Tag Archives: Merck

Novartis takes total control of Alcon

Posted on January 4, 2010 by xtello

In a $28Bn USD operation, the Swiss Pharmaceutical buys the 52% of Alcon’s remanent stock from Nestlé. Novartis would own an approximate 77 percent interest in Alcon. The operation goes at least one and a half year earlier than estimated in … Continue reading →

Posted in Alta Dirección, Mercadotecnia, Salud | Tagged Acquisition, Alcon, Compra, Daniel Vasella, Fusión, Glaucoma, Merck, Merger, Nestle, Novartis, Oftalmología, Ophtalmology, Pfizer, Sanofi Aventis, Surgical devices | Leave a comment

Abbott buys Solvay Pharma Division on $7Bn USD

Posted on September 27, 2009 by xtello

According to information published today at the Wall Street Journal, Abbott will buy Solvay’s Pharmaceutical Division in a $7Bn USD deal. The official communication could be published by both companies as early as monday morning. With this deal Abbott is … Continue reading →

Posted in Alta Dirección, Mercadotecnia, Ventas | Tagged Abbott, Acquisition, Adquisición, Cholesterol, Colesterol, Flu, Fusión, H1N1, Hipertensión, Hypertension, Infuenza, Merck, Merger, Pfizer, Solvay, The Wall Street Journal, Triglicéridos, Triglycerides, Vaccine, Vacuna | Leave a comment

Pharma: Trust Deficit or the Biggest Image Problem ever faced?

Posted on April 5, 2009 by xtello

It was Saturday afternoon; April 4th, to be precise. 7-time Tour de France winner and full-time cancer fighter: Lance Armstrong was in his born-state Texas, riding to give a speech in the PhRMA meeting in San Antonio. From his … Continue reading →

Posted in Alta Dirección, Mercadotecnia, Opinión, Salud, Ventas | Tagged Acomplia, Advertising, Alzheimer, Alzheimer’s, AstraZeneca, Bioethics Blog, Chris MacDonald, CME, Code, Código, Continuing Medical Education, Covalence, Cuidado de la Salud, David Brennan, Déficit de confianza, Diabetes, Dick Clark, Direct to consumer, Dislipidemia, DTC, DTP Direct to patient, Educación Médica Contínua, Esclerosis Múltiple, Estados Unidos, Europa, Europe, FDA, Forbes, George Koroneos, Health Care, Insurance, JAMA, Jonathan Rockoff, Kathryn Metcalfe, Kevin Pho, Lance Armstrong, Merck, Multiple Sclerosis, No Free Lunch, Paul H. Rubin, Pfizer, PharmExec.com, PhRMA, PR, Promoción, Promotion, Public Relations, Publicidad, Regulatorio, Regulatory, Relaciones Públicas, Reputación, Reputation, San Antonio, Schering Plough, Seguro, Tour de France, Trust Deficit, Twitter, USA, Vioxx, WSJ Health Blog | 3 Comments

2009 Pharma Mergers. A comprehensive analysis facing the future.

Posted on March 29, 2009 by xtello

The last two months have been full of surprises in the Pharmaceutical arena. January was not even ending, when Pfizer was announcing its intentions of taking over Wyeth. Just some days after a month later and after a more-than-nervous weekend, … Continue reading →

Posted in Alta Dirección, Mercadotecnia, Opinión, Salud, Ventas | Tagged Acquisitions, Adquisiciones, Allergan, ALTANA, American College of Cardiology, Artritis, Biotechnology, Biotecnología, Bloomberg, Botox, COPD, Cozaar, Crestor, Dolor, EPOC, Federal Trade Commission, Forbes, Fosamax, Fusión, Genentech, Genéricos, Generics, Golimumab, GSK, Jean Françoise Dehecq, Johnson & Johnson, JUPITER, Kendrick, Medley, Merck, Merger, Mevacor, Nycomed, Osteoporosis, Pain, Pfizer, Preotact, PricewaterhouseCoopers, Remicade, Rheumatoid Arthritis, Roche, Salk Institute, Schering Plough, Teva, Tromboembolismo venoso, Venous thromboembolism, Wyeth, Zentiva, Zocor | 3 Comments

La FDA anuncia medicamentos (literalmente).

Posted on March 28, 2009 by xtello

Mucho se ha hablado sobre la publicidad de medicamentos y sus ventajas y desventajas de que esta sea abierta al público. Para los defensores de la no publicidad abierta sobre productos éticos (fracciones I-IV), el mito de “evitar la auto-prescripción” … Continue reading →